Microbial And Molecular Differences According To The Location of Head And Neck Cancers

Yun Kyeong Kim

Pusan National University

Eun Jung Kwon

Pusan National University

Yeuni Yu

Pusan National University Hospital

Jayoung Kim

Pusan National University

Soo-Yeon Woo

Pusan National University

Hee-Sun Choi

Pusan National University

Munju Kwon

Pusan National University

Keehoon Jung

Seoul National University College of Medicine

Hyung-Sik Kim

Pusan National University

Hae Ryoung Park

Pusan National University

Dongjun Lee

Pusan National University

Yun Hak Kim (✉ yunhak10510@pusan.ac.kr)

Pusan National University

Research Article

Keywords: Microbiome, HNSCC, Oral cancer, Non-oral cancer

Posted Date: January 24th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-876109/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at Cancer Cell International on March 26th, 2022. See the published version at <https://doi.org/10.1186/s12935-022-02554-6>.

Abstract

Background : Microbiome has been shown to substantially contribute to some cancers. However, the diagnostic implications of microbiome in head and neck squamous cell carcinoma (HNSCC) remain unknown.

Methods : we report for the first time, the molecular difference in the microbiome of oral and non-oral HNSCC. Primary data was downloaded from the Kraken-TCGA dataset. The molecular differences in the microbiome of oral and non-oral HNSCC were identified using the linear discriminant analysis effect size method.

Results : In the study, the common microbiomes in oral and non-oral cancers were *Fusobacterium*, *Treponema*, and *Selenomonas* and *Clostridium* and *Massilia*, respectively. We found unique microbial signatures that positively and negatively correlated with Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in oral cancer and negatively correlated KEGG pathways in non-oral cancer. In oral cancer, positively correlated genes were mostly found in bacterial infection pathways, while negative correlated genes were involved in HTLV-I infection, signal transduction, cell adhesion, and cancer-associated pathway. In non-oral cancer, positively correlated genes did not show any significant results, and negatively correlated genes showed results from focal adhesion pathway and regulation of actin cytoskeleton pathway.

Conclusions : These results could help in understanding the underlying biological mechanisms of the microbiome of oral and non-oral HNSCC. Microbiome-based oncology diagnostic tool warrants further exploration.

Introduction

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with 890,000 new cases and 450,000 deaths in 2018[1, 2]. HNSCC accounts for about 6% of all cancers and 1-2% of deaths due to neoplastic diseases [3-5]. Cigarette smoking, tobacco use, and positive human papillomavirus status are well-known risk factors for HNSCC[6], with approximately three-quarters of HNSCC cases attributed to cigarette smoking and tobacco use[7, 8]. HNSCC is a heterogeneous disease and tumours are distinguished based on location. HNSCC originates from the epithelial cells in the laryngeal and oropharynx, lips, mouth, nasopharynx, or larynx.

Trillions of microbes have evolved and continue to live on and within human beings[9]. Numerous studies have suggested a link between the microbiota, which exist in various organs (e.g., gut and placenta) and pathological conditions such as neurologic diseases, metabolic disorders, and cancers[10-13]. With the development of omics technologies, such as metagenomics, transcriptomics, and proteomics, substantial evidence has been accumulated regarding the relationship of microorganisms and various diseases, including cancers[14].

The gut microbiome has been associated with various disorders, especially malignant tumours. The gut microbiome is involved in biological processes, including modulating the metabolic phenotype, regulating epithelial development, and influencing innate immunity[15]. Chronic diseases such as obesity, inflammatory bowel disease, diabetes mellitus, metabolic syndrome, atherosclerosis, alcoholic liver disease, non-alcoholic fatty liver disease, cirrhosis, and hepatocellular carcinoma are associated with the human microbiome[16]. Several studies have demonstrated that gut microbiome dysbiosis is associated with tumourigenesis and/or tumour growth across cancer types, including colon, hepatocellular carcinoma, gastric, and breast[10, 15]. Moreover, the

gut microbiome has been demonstrated to play a key role in the response to cancer therapy, such as chemotherapy, immune checkpoint blockade, and stem cell transplant[10]. For immune checkpoint blockade response, differential gut microbiome signatures exist in patients who respond to immune checkpoint blockade treatment[17-19].

Although intratumoral microbiota has not been studied as much as the gut microbiota, the importance of microbiota in tumours is increasing, with studies showing that it affects the response to cancer treatment[10, 20-23]. Intratumoral bacteria, which are metabolically active, can alter the chemical structure of anti-cancer drugs[24, 25]. In addition, *Fusobacterium nucleatum* in colorectal tumour promotes resistance to chemotherapy through modulation of autophagy[26]. HNSCC, especially oral squamous cell carcinoma (OSCC), is the most prevalent and commonly studied cancer associated with bacterial infection, and is the most common malignancy of the head and neck worldwide[27]. Two prominent oral pathogens, *Porphyromonas gingivalis*, and *F. nucleatum* have been reported to promote tumour progression in mice[28]. Periodontitis is an infectious disease causing chronic inflammation in the oral cavity[29, 30]. Periodontitis has been linked to various cancers, including oesophageal and oropharyngeal cancers[27]. Several studies have found that the risk of developing OSCC may increase with periodontal disease[31, 32], and periodontal disease increases the risk of oral cancer even after adjusting for significant risk factors[33, 34]. Herein, we investigated the underlying molecular differences of the microbiome of oral cancer and non-oral HNSCC.

Methods

Microbiome datasets & TCGA RNA-sequencing datasets

We downloaded Kraken-TCGA(The Cancer Genome Atlas) -Raw-Data (n=17625) from microbial count datasets[35] for this study. Primary tumours were selected from HNSCC of microbiome data, classified into RNA and WGS, and combined with TCGA clinical information to separate oral and non-oral subtype. RNA-expression sequencing and clinical data sets of 546 HNSCC samples were downloaded from the Broad GDAC Firehose [36] on 20 Feb 2020. The samples were categorised based on the site of occurrence as either oral cancer (alveolar ridge, base of the tongue, buccal mucosa, floor of the mouth, hard palate, oral cavity, oral tongue) or non-oral cancer (hypopharyngeal, larynx, lips, oropharynx, tonsil). Preprocessing was used with the R program (version 4.0.3)[37].

Linear discriminant analysis effect size (LEfSe)

To identify significantly different bacteria (as biomarkers) between the two groups at the genus level, taxa summaries were reformatted and inputted into LEfSe via the Huttenhower Lab Galaxy Server[38]. The LDA values of oral and non-oral HNSCC microbiome data of RNA and DNA were obtained. Then, we obtained common bacteria of RNA and DNA with the threshold on the logarithmic LDA score for discriminative features of 2.0. In the settings of LEfSe, the Kruskal-Wallis sum-rank test ($\alpha = 0.05$) was used to detect taxa with significant differential abundance. We used the LDA method to estimate the effect size of the abundant genus level[38].

Phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt) and ANOVA-like differential expression (ALDEx2)

The name of the common bacteria was changed to ID of Greengenes (97% taxonomy) (version 13.5) (<http://greengenes.lbl.gov>) and used as an input file. PICRUSt was performed using the Galaxy web application, which was used to predict bacterial metabolic contributions of oral rich and non-oral rich bacteria, respectively[39]. To filter the results of the PICRUSts, we merged results of oral rich and non-oral rich bacteria, and used the ALDEx2[40] to obtain top five pathways with a p-value of 0.05 or less.

Correlation analysis

A correlation analysis was performed with respect to the RNA expression data and common bacteria data of oral and non-oral HNSCC. Using the Spearman correlation test, genes with oral/non-oral correlation coefficients $r > 0.15$ and $r < -0.15$ were obtained. Significance levels were considered at $P < 0.05$.

Protein-protein interaction (PPI) analysis & Hub gene

PPI analysis of correlated genes was performed using the plug-in Search Tool for the Retrieval of Interacting Genes (STRING) app (version 1.5.1)[41]. The results of the analysis were imported into Cytoscape (version 3.8.2) [42] to establish a network model. The plug-in app cytohubba (version 0.1)[43] in Cytoscape was downloaded and installed. The top ten scores of the degree algorithm were taken as the criteria to screen out the hub genes with high connectivity in the gene expression network.

KEGG pathway and gene ontology (GO)

KEGG pathway and GO analysis were performed on the DAVID website[44] with the genes in the node table resulting from the PPI. Then, the genetic symbol was transferred to entrezID using the org.Hs.eg.db (version 3.12.0) package[45] with the same input file from the PPI for subsequent analysis. The results of enhanced GO entries and KEGG were visualised as path point plots using clusterProfiler (version 3.18.1), ggplot (version 3.3.5), and Enrichplot2 (version 1.10.2) packages. GO and KEGG analysed the used data with statistically significant false discovery rates < 0.05 .

Results

Characterisation of unique microbial signatures of oral and non-oral HNSCC

To evaluate the unique microbial signatures of oral and non-oral HNSCC, we analysed Kraken-TCGA data sets using the linear discriminant analysis (LDA) method. We divided 691 HNSCC samples into 172 DNA whole genome sequencing (WGS) data and 519 RNA sequencing data (Fig. 1). Next, we analysed RNA sequencing as subtypes divided into 338 oral cancer and 181 non-oral cancer. DNA WGS data were also analysed as 124 oral and 48 non-oral subtypes. Medical information related to these samples is described in Table 1.

Investigation of the common microbiome of oral and non-oral HNSCC

The relatively enriched microbiome of oral and non-oral HNSCC are shown in Fig. 2a and 2b. The enriched microbiomes in oral HNSCC were *Fusobacterium*, *Treponema*, and *Selenomonas*, and the enriched microbiomes in non-oral HNSCC were *Clostridium* and *Massilia*, as determined by the linear discriminant analysis effect size (LEfSe) method (Fig. 2a and 2b). The distribution of count data for each microbiome subtypes is depicted in Fig. 2b – 2g. Microbiome with higher levels of distribution in oral HNSCC were *Selenomonas*, *Fusobacterium*, and

Treponema, and microbiome with higher levels of distribution in non-oral HNSCC were Clostridium and Massilia (Fig. 2a and 2b).

Microbial Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and protein network of oral and non-oral HNSCC

We analysed the molecular mechanism of the microbiome of oral and non-oral HNSCC using KEGG pathway analysis and protein network analysis (Fig. 3, Table 1, and Table 2). We found unique microbial signatures that positively correlated KEGG pathways in oral HNSCC, negatively correlated KEGG pathways in oral HNSCC, and negatively correlated KEGG pathways in non-oral HNSCC (Fig. 3). In oral HNSCC, positively correlated genes were mostly found in bacterial infection pathways, and the genes involved in HTLV-I infection, signal transduction, cell adhesion, and cancer-associated pathway were negatively correlated with the disease. In non-oral cancer, positively correlated genes did not show any significant results, and negatively correlated genes showed results from focal adhesion and regulation of actin cytoskeleton. In addition, we conducted a pathway and gene expression analysis using microbial data of subtypes from each oral and non-oral HNSCC (Table 2 and Supplementary Table 1). Rich microbiome within non-oral cancer was found to be associated with biosynthesis and metabolism of glycan, transport, catabolism, and biosynthesis of other secondary metabolites. Rich microbiome within oral cancer was involved in the biodegradation and metabolism of xenobiotics, neurodegenerative diseases, and the circulatory system. We showed the KEGG pathway of protein-protein interaction (PPI) node table genes by correlating mRNA expression data with the microbiome (Table 3). The results of the phylogenetic investigation of communities by reconstruction of unobserved states (PICRUST) analysis are shown in Supplementary Fig. 1. The dots represent the differences in the abundance of oral vs non-oral HNSCC KEGG pathways. Further, we analysed the hub genes of oral and non-oral HNSCC using the Cytohubba method in Cytoscape software and identified positive and negative expression related to them (Supplementary Table 2).

Discussion

The microbiome plays an important role in the human host and participates in the development of a wide variety of diseases, such as cancer[9]. The tumor microbiome is associated with a chronic inflammatory state and modulates the initiation and development of various cancers, such as lung, breast, colon, gastric, pancreatic, cholangiocarcinoma, ovarian, and prostate cancers[10, 20-23, 46-48]. In colorectal cancer (CRC), transplant of stool containing the tumor microbiome from patients with CRC can induce polyp formation[49, 50]. Moreover, some bacterial species (*F. nucleatum*) can stimulate an inflammatory state that can promote carcinogenesis via increased production of reactive oxygen species[51], induction of proinflammatory toxins[52, 53], and suppression of anti-tumor immune functions[54, 55]. In this study, we identified for the first time, the tumor microbiome in oral and non-oral HNSCC.

We systematically selected five microbiomes as unique microbial signatures of oral and non-oral HNSCC. Microbiomes with higher levels of distribution in oral HNSCC were *Selenomonas*, *Fusobacterium*, and *Treponema*, while microbiomes with higher levels of distribution in non-oral HNSC were *Clostridium* and *Massilia*. Further, we demonstrated the molecular mechanisms for positively correlated KEGG pathways in oral HNSCC, negatively correlated KEGG pathways in oral HNSCC, and negatively correlated KEGG pathways in non-oral cancer from HNSCCs (Fig. 4).

The prevention and treatment of diseases by targeting the microbiome have been widely investigated[27]. Modulation of the microbiome may also contribute to the treatment of cancer[56]. Cancer therapy requires an intact commensal microbiome that mediates the therapy effects by modulating functions of myeloid-derived suppressor cells in the tumor microenvironment[21, 56, 57]. Some studies have shown the deleterious effects of antibiotics on the treatment of cancer[10, 58]. Patients with metastatic renal cell carcinoma or non-small-cell lung cancer had significantly worse survival outcomes if they received antibiotics just before or just after the initiation of treatment with immune checkpoint blockade[59]. In addition, patients who received anti-Gram-positive antibiotics along with cyclophosphamide for chronic lymphocytic leukemia or cisplatin for relapsed lymphoma had a lower overall response rate[52, 60]. These microbiomes may confer susceptibility to certain cancers, either through a direct effect by the local presence within the tumor microenvironment or via the systemic impact of the microbiome from a distant location, such as the gut and the skin[61].

Conclusions

Taken together, stress conditions, such as diet, antigen exposure, medications, and stress are important factors that contributing to the state of health and also affect the microbiome[35]. This field is young, and we are left with many unanswered questions - especially regarding the mechanism of action as well as the group of bacterial species that are most important in mediating antitumor effects. Multifaceted strategies are needed to modulate precision medicine and treat disease. Efforts are currently underway to enhance therapeutic responses and/or abrogate treatment-associated toxicity chemotherapeutic agents via modulation of the microbiome.

Abbreviations

TCGA: The Cancer Genome Atlas

ALDEx2: ANOVA-like differential expression tool for high-throughput sequencing data

CRC: colorectal cancer

GO: Gene Ontology

HNSCC: head and neck squamous cell carcinoma

HTLV-I: Human T-cell lymphotropic virus type 1

KEGG: Kyoto Encyclopedia of Genes and Genomes

LDA: linear discriminant analysis

LDA: Linear Discriminant Analysis

LEfSe: linear discriminant analysis effect size

OSCC: Oral squamous cell carcinoma

PICRUSt: phylogenetic investigation of communities by reconstruction of unobserved states

PPI: Protein-protein interaction

STRING: Search Tool for the Retrieval of Interacting Genes/Proteins

TCGA: The Cancer Genome Atlas

WGS: whole genome sequencing

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors agreed on the manuscript.

Availability of data and materials

All the data were available on the manuscript or from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no conflict of interest.

Funding

This work was supported by the National Research Foundation of Korea (NRF-2018R1A5A2023879, 2020R1A2C1005203, 2020R1C1C1003741, and 2021R1A2C4001466).

A portion of the data used for this study were obtained from the Genome-InfraNet (IDs: 1711020733, 1711032008, and 1711028992) of the Korea Bioinformation Center.

Authors' contributions

DL and YHK initiated the study and guided the work. YKK and EJK collected, normalised, and interpreted the data. YY, JK, SYW, HSC, MK, KJ, HSK, and HRP analysed the experimental data. All authors wrote the manuscript with input from all co-authors.

Acknowledgments

Not applicable.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: **Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.** *CA Cancer J Clin* 2018, **68**:394-424.

2. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A, Bray F: **Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.** *Int J Cancer* 2019, **144**:1941-1953.
3. Attar E, Dey S, Hablas A, Seifeldin IA, Ramadan M, Rozek LS, Soliman AS: **Head and neck cancer in a developing country: A population-based perspective across 8years.** *Oral Oncology* 2010, **46**:591-596.
4. Nandakumar A: **Survival in head and neck cancers-results of a multi-institution study.** *Asian Pacific Journal of Cancer Prevention* 2016, **17**:1745-1754.
5. Pai SI, Westra WH: **Molecular Pathology of Head and Neck Cancer: Implications for Diagnosis, Prognosis, and Treatment.** *Annual Review of Pathology: Mechanisms of Disease* 2009, **4**:49-70.
6. Farsi NJ, Rousseau M-C, Schlecht N, Castonguay G, Allison P, Nguyen-Tan PF, Soulières D, Coutlée F, Hier M, Madathil S: **Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol.** *Carcinogenesis* 2017, **38**:1188-1195.
7. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni JF: **Smoking and drinking in relation to oral and pharyngeal cancer.** *Cancer research* 1988, **48**:3282-3287.
8. Hashibe M, Brennan P, Chuang S-C, Boccia S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, et al: **Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium.** *Cancer Epidemiology Biomarkers & Prevention* 2009, **18**:541-550.
9. Koh A, Bäckhed F: **From association to causality: the role of the gut microbiota and its functional products on host metabolism.** *Molecular cell* 2020, **78**:584-596.
10. Helmink BA, Khan MW, Hermann A, Gopalakrishnan V, Wargo JA: **The microbiome, cancer, and cancer therapy.** *Nature medicine* 2019, **25**:377-388.
11. Czesnikiewicz-Guzik M, Müller DN: **Scientists on the spot: salt, the microbiome, and cardiovascular diseases.** *Cardiovascular research* 2018, **114**:e72-e73.
12. Hansen JJ, Sartor RB: **Therapeutic manipulation of the microbiome in IBD: current results and future approaches.** *Current treatment options in gastroenterology* 2015, **13**:105-120.
13. Kim D, Zeng MY, Núñez G: **The interplay between host immune cells and gut microbiota in chronic inflammatory diseases.** *Experimental & molecular medicine* 2017, **49**:e339-e339.
14. Salihoğlu R, Önal-Süzek T: **Tissue Microbiome Associated With Human Diseases by Whole Transcriptome Sequencing and 16S Metagenomics.** *Frontiers in Genetics* 2021, **12**:281.
15. Papotto PH, Yilmaz B, Silva-Santos B: **Crosstalk between $\gamma\delta$ T cells and the microbiota.** *Nature Microbiology* 2021:1-8.

16. Ley RE, Turnbaugh PJ, Klein S, Gordon JI: **Human gut microbes associated with obesity.** *nature* 2006, **444**:1022-1023.
17. Routy B, Le Chatelier E, Derosa L, Duong CP, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP: **Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors.** *Science* 2018, **359**:91-97.
18. Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF: **The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients.** *Science* 2018, **359**:104-108.
19. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews M, Karpinets T, Prieto P, Vicente D, Hoffman K, Wei S: **Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients.** *Science* 2018, **359**:97-103.
20. Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC, Figueiredo C: **Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota.** *Gut* 2018, **67**:226-236.
21. Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A, Mohan N, Aykut B, Usyk M, Torres LE: **The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression.** *Cancer discovery* 2018, **8**:403-416.
22. Sfanos KS, Sauvageot J, Fedor HL, Dick JD, De Marzo AM, Isaacs WB: **A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms.** *The Prostate* 2008, **68**:306-320.
23. Urbaniak C, Gloor GB, Brackstone M, Scott L, Tangney M, Reid G: **The microbiota of breast tissue and its association with breast cancer.** *Applied and environmental microbiology* 2016, **82**:5039-5048.
24. Lehouritis P, Cummins J, Stanton M, Murphy CT, McCarthy FO, Reid G, Urbaniak C, Byrne WL, Tangney M: **Local bacteria affect the efficacy of chemotherapeutic drugs.** *Scientific reports* 2015, **5**:1-12.
25. Panebianco C, Andriulli A, Pazienza V: **Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies.** *Microbiome* 2018, **6**:1-13.
26. Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N: **Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy.** *Cell* 2017, **170**:548-563. e516.
27. Irfan M, Delgado RZR, Frias-Lopez J: **The oral microbiome and cancer.** *Frontiers in immunology* 2020, **11**.
28. Gallimidi AB, Fischman S, Revach B, Bulvik R, Maliutina A, Rubinstein AM, Nussbaum G, Elkin M: **Periodontal pathogens Porphyromonas gingivalis and Fusobacterium nucleatum promote tumor progression in an oral-specific chemical carcinogenesis model.** *Oncotarget* 2015, **6**:22613.
29. Hajishengallis G: **Immunomicrobial pathogenesis of periodontitis: keystones, pathobionts, and host response.** *Trends in immunology* 2014, **35**:3-11.

30. Hajishengallis G: **Periodontitis: from microbial immune subversion to systemic inflammation.** *Nature Reviews Immunology* 2015, **15**:30-44.
31. Galvão-Moreira LV, da Cruz MCFN: **Oral microbiome, periodontitis and risk of head and neck cancer.** *Oral oncology* 2016, **53**:17-19.
32. Karmakar S, Kar A, Thakur S, Rao VU: **Periodontitis and oral Cancer-A striking link.** *Oral oncology* 2020, **106**:104630.
33. Fitzpatrick SG, Katz J: **The association between periodontal disease and cancer: a review of the literature.** *Journal of dentistry* 2010, **38**:83-95.
34. Javed F, Warnakulasuriya S: **Is there a relationship between periodontal disease and oral cancer? A systematic review of currently available evidence.** *Critical reviews in oncology/hematology* 2016, **97**:197-205.
35. Poore GD, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, Kosciulek T, Janssen S, Metcalf J, Song SJ, et al: **Microbiome analyses of blood and tissues suggest cancer diagnostic approach.** *Nature* 2020, **579**:567-574.
36. Deng M, Brägelmann J, Kryukov I, Saraiva-Agostinho N, Perner S: **FirebrowseR: an R client to the Broad Institute's Firehose Pipeline.** *Database* 2017, **2017**:baw160.
37. Team RC: **R: A language and environment for statistical computing.** 2013.
38. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C: **Metagenomic biomarker discovery and explanation.** *Genome Biol* 2011, **12**:R60.
39. Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC, Burkepile DE, Vega Thurber RL, Knight R, et al: **Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences.** *Nature Biotechnology* 2013, **31**:814-821.
40. Fernandes AD, Reid JN, Macklaim JM, McMurrough TA, Edgell DR, Gloor GB: **Unifying the analysis of high-throughput sequencing datasets: characterizing RNA-seq, 16S rRNA gene sequencing and selective growth experiments by compositional data analysis.** *Microbiome* 2014, **2**:15.
41. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P: **STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets.** *Nucleic acids research* 2019, **47**:D607-D613.
42. Doncheva NT, Morris JH, Gorodkin J, Jensen LJ: **Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data.** *Journal of Proteome Research* 2019, **18**:623-632.
43. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY: **cytoHubba: identifying hub objects and sub-networks from complex interactome.** *BMC Syst Biol* 2014, **8 Suppl 4**:S11.
44. Jiao X, Sherman BT, Huang DW, Stephens R, Baseler MW, Lane HC, Lempicki RA: **DAVID-WS: a stateful web service to facilitate gene/protein list analysis.** *Bioinformatics* 2012, **28**:1805-1806.

45. Yu G, Wang L-G, Han Y, He Q-Y: **clusterProfiler: an R package for comparing biological themes among gene clusters.** *Omics: a journal of integrative biology* 2012, **16**:284-287.
46. Banerjee S, Tian T, Wei Z, Shih N, Feldman MD, Alwine JC, Coukos G, Robertson ES: **The ovarian cancer oncobiome.** *Oncotarget* 2017, **8**:36225.
47. Mao Q, Jiang F, Yin R, Wang J, Xia W, Dong G, Ma W, Yang Y, Xu L, Hu J: **Interplay between the lung microbiome and lung cancer.** *Cancer letters* 2018, **415**:40-48.
48. Aviles-Jimenez F, Guitron A, Segura-Lopez F, Mendez-Tenorio A, Iwai S, Hernandez-Guerrero A, Torres J: **Microbiota studies in the bile duct strongly suggest a role for *Helicobacter pylori* in extrahepatic cholangiocarcinoma.** *Clinical Microbiology and Infection* 2016, **22**:178. e111-178. e122.
49. Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WKK, Ng SC, Tsoi H, Dong Y, Zhang N, et al: **Gut mucosal microbiome across stages of colorectal carcinogenesis.** *Nature Communications* 2015, **6**:8727.
50. Lu Y, Chen J, Zheng J, Hu G, Wang J, Huang C, Lou L, Wang X, Zeng Y: **Mucosal adherent bacterial dysbiosis in patients with colorectal adenomas.** *Scientific Reports* 2016, **6**:26337.
51. Mangerich A, Knutson CG, Parry NM, Muthupalani S, Ye W, Prestwich E, Cui L, McFaline JL, Mobley M, Ge Z: **Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer.** *Proceedings of the National Academy of Sciences* 2012, **109**:E1820-E1829.
52. Wu S, Rhee K-J, Albesiano E, Rabizadeh S, Wu X, Yen H-R, Huso DL, Brancati FL, Wick E, McAllister F: **A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses.** *Nature medicine* 2009, **15**:1016-1022.
53. Boleij A, Hechenbleikner EM, Goodwin AC, Badani R, Stein EM, Lazarev MG, Ellis B, Carroll KC, Albesiano E, Wick EC: **The *Bacteroides fragilis* toxin gene is prevalent in the colon mucosa of colorectal cancer patients.** *Clinical Infectious Diseases* 2015, **60**:208-215.
54. Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, Enk J, Bar-On Y, Stanietsky-Kaynan N, Copenhagen-Glazer S: **Binding of the Fap2 protein of *Fusobacterium nucleatum* to human inhibitory receptor TIGIT protects tumors from immune cell attack.** *Immunity* 2015, **42**:344-355.
55. Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan T-J, Campbell BJ, Abujamel T, Dogan B, Rogers AB: **Intestinal inflammation targets cancer-inducing activity of the microbiota.** *science* 2012, **338**:120-123.
56. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S: **Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.** *Science* 2013, **342**:967-970.
57. Orberg ET, Fan H, Tam AJ, Dejea CM, Shields CD, Wu S, Chung L, Finard BB, Wu X, Fathi P: **The myeloid immune signature of enterotoxigenic *Bacteroides fragilis*-induced murine colon tumorigenesis.** *Mucosal immunology* 2017, **10**:421-433.

58. Arthur JC, Gharaibeh RZ, Uronis JM, Perez-Chanona E, Sha W, Tomkovich S, Mühlbauer M, Fodor AA, Jobin C: **VSL# 3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer.** *Scientific reports* 2013, **3**:1-9.

59. Derosa L, Hellmann M, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski A, Arbour K, Chaft J: **Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.** *Annals of Oncology* 2018, **29**:1437-1444.

60. Pflug N, Kluth S, Vehreschild JJ, Bahlo J, Tacke D, Biehl L, Eichhorst B, Fischer K, Cramer P, Fink A-M: **Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota.** *Oncoimmunology* 2016, **5**:e1150399.

61. Jacobsohn DA, Vogelsang GB: **Acute graft versus host disease.** *Orphanet journal of rare diseases* 2007, **2**:1-9.

Tables

Table 1 Patient’s characteristics

RNA		TCGA-HNSCC (N= 519)		
		Oral (338)	Non-oral (181)	P-value
Age	< 55	94	56	0.5172
	≥55	244	125	
Gender	Female	105	31	0.005043**
	Male	233	150	
Clinical Stage	I	19	8	0.005159**
	II	56	18	
	III	63	18	
	IVA	161	92	
	IVB	7	5	
	IVC	0	1	
	Not available	32	39	
Race	American Indian or Alaska native	1	1	0.01246*
	Asian	10	1	
	Black or African American	22	26	
	White	295	148	
	Not available	10	5	
DNA		TCGA-HNSCC (N=172)		
		Oral (124)	Non-oral (48)	P-value
Age	< 55	40	20	0.3256
	≥55	84	28	
Gender	Female	42	5	0.003688**
	Male	82	43	
Clinical Stage	I	8	3	0.005159**
	II	23	3	
	III	19	7	
	IVA	59	17	
	IVB	1	2	

	IVC	0	0	
	Not available	14	16	
Race	American Indian or Alaska native	0	0	0.2463
	Asian	2	0	
	Black or African American	6	6	
	White	114	42	
	Not available	2	0	

* P < 0.05 ** P < 0.01 *** P < 0.001

Chi-squared test was done for age, gender and Fisher's exact-test was done for clinical stage, race
HNSCC, head and neck squamous cell carcinoma

Table 2 Results of PICRUSt KEGG pathway enrichment analysis

	LEVEL 1	LEVEL 2	LEVEL 3	rab.win.NO	rab.win.O	diff.btw
Oral rich bacteria	Metabolism	Xenobiotics Biodegradation and Metabolism	Caprolactam degradation	1.6747495	8.430766	6.279402
	Human Diseases	Neurodegenerative Diseases	Huntington's disease	2.4877375	8.382426	5.413706
	Organismal Systems	Circulatory System	Cardiac muscle contraction	2.907211	8.378313	5.100822
	Organismal Systems	Circulatory System	Mineral absorption	2.8999521	8.38446	5.017036
	Human Diseases	Neurodegenerative Diseases	Parkinson's disease	2.9033953	8.351826	5.003632
Non-oral rich bacteria	Metabolism	Glycan Biosynthesis and Metabolism	Other glycan degradation	10.85589	-0.53392	-11.3316
	Metabolism	Glycan Biosynthesis and Metabolism	Glycosphingolipid biosynthesis – globo series	10.81923	0.339303	-10.5042
	Cellular Processes	Transport and Catabolism	Lysosome	10.830371	0.335549	-10.4971
	Metabolism	Glycan Biosynthesis and Metabolism	Glycosaminoglycan degradation	10.836729	0.609203	-10.0124
	Metabolism	Biosynthesis of Other Secondary Metabolites	Flavone and flavonol biosynthesis	10.838202	1.609486	-9.10254

BH < 0.05 compared to the oral and non-oral (ALDEx2), BH, Benjamini-Hochberg

diff.btw cut off > abs(5)

rab.win.NO: a vector containing the median clr value for each feature in non-oral, clr, centred log-ratio

rab.win.O: a vector containing the median clr value for each feature in oral

diff.btw: a vector containing the per-feature median difference between condition non-oral and oral

PICRUSt, phylogenetic investigation of communities by reconstruction of unobserved states; KEGG, Kyoto Encyclopedia of Genes and Genomes

Table 3 DAVID gene-annotation enrichment analysis of KEGG pathway

	ID	KEGG pathway	count	P-value	FDR	Genes
Positively correlated genes in oral cancer	hsa05130	Pathogenic Escherichia coli infection	6	1.65E-04	0.015558519	<i>TUBA1C, TUBB6, ARPC1A, ARPC5L, TUBB4B, TUBA4A</i>
	hsa05132	Salmonella infection	7	1.97E-04	0.015558519	<i>IL1A, KLC3, CXCL8, IL1B, ARPC1A, ARPC5L, IL18</i>
Negatively correlated genes in oral cancer	hsa04070	Phosphatidylinositol signalling system	11	6.56E-04	0.024540845	<i>PRKCB, INPP5D, PI4KA, ITPR1, MTMR8, PIK3R3, PLCE1, PIP5K1B, PIK3R1, PIK3CG, PIK3R5</i>
	hsa04360	Axon guidance	12	0.001414405	0.035531246	<i>ROBO2, SEMA5B, NRP1, SEMA3D, SEMA3G, NTN4, UNC5C, SLIT3, SLIT2, PLXNC1, NTN1, EPHA3</i>
	hsa04514	Cell adhesion molecules (CAMs)	14	3.09E-04	0.019256786	<i>NLGN3, SELPLG, VCAM1, ITGB2, NRXN3, PTPRM, ITGAL, SELP, SPN, PTPRC, PDCD1, NCAM2, TIGIT, NEO1</i>
	hsa04666	Fc gamma R-mediated phagocytosis	12	3.63E-05	0.006794491	<i>HCK, SCIN, PTPRC, PRKCB, INPP5D, WAS, PIK3R3, PIP5K1B, PIK3R1, VAV1, PIK3CG, PIK3R5</i>
	hsa04810	Regulation of actin cytoskeleton	16	0.001520053	0.035531246	<i>ITGB2, WAS, PIK3R3, PIK3R1, ITGAL, IQGAP2, PIK3CG, VAV1, PIK3R5, FGF7, SCIN, ITGA11,</i>

						<i>FGF18, PIP5K1B, NCKAP1L, PPP1R12B</i>
	hsa04960	Aldosterone-regulated sodium reabsorption	7	9.58E-04	0.02984755	<i>PRKCB, INSR, PIK3R3, PIK3R1, PIK3CG, NR3C2, PIK3R5</i>
	hsa05144	Malaria	8	5.75E-04	0.024540845	<i>SELP, VCAM1, LRP1, TGFB3, ITGB2, TLR9, ITGAL, THBS4</i>
	hsa05166	HTLV-I infection	20	2.00E-04	0.018711974	<i>FZD1, MAP3K3, NRP1, EGR2, SMAD4, SPI1, VCAM1, TGFB3, FZD7, ITGB2, PIK3R3, PIK3R1, ITGAL, ELK1, PIK3CG, PIK3R5, IL2RB, LTA, MAP3K14, PRKACB</i>
	hsa05205	Proteoglycans in cancer	15	0.002607227	0.048755147	<i>FZD1, PRKCB, FZD7, PTCH1, ITPR1, PIK3R3, PIK3R1, HSPG2, ELK1, PIK3CG, PIK3R5, HCLS1, PLCE1, PPP1R12B, PRKACB</i>
	hsa05210	Colorectal cancer	8	0.002372152	0.048755147	<i>SMAD4, TGFB3, TCF7, LEF1, PIK3R3, PIK3R1, PIK3CG, PIK3R5</i>
Negatively correlated genes in non-oral cancer	hsa04510	Focal adhesion	7	8.31E-04	0.045276517	<i>ACTN3, ACTN1, ITGB3, ITGAV, FLNB, ITGB6, TLN1</i>
	hsa04810	Regulation of actin cytoskeleton	8	1.26E-04	0.01373759	<i>ENAH, ACTN3, ACTN1, ITGB3, F2R, MSN, ITGAV, ITGB6</i>

KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate

Figures

Figure 1

Pipeline flow chart throughout the study

Figure 2

Linear discriminant analysis effect size (LEfSe) analyses and distribution of the microbiome by subtype

LEfSe analysis of microbiome composition between oral and non-oral-associated cancers was performed on (a) bacterial DNA and (b) bacterial RNA, respectively. Bacteria species enriched in oral cancer had a positive linear discriminant analysis (LDA) score, while bacteria species enriched in non-oral cancer had a negative score. Microbiomes with higher levels of distribution in oral cancer were (c) *Selenomonas*, (d) *Fusobacterium*, and (e) *Treponema*. Microbiomes with higher levels of distribution in non-oral cancer were (f) *Clostridium* and (g) *Massilia*

Figure 3

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis

(a) Significantly enriched KEGG pathways of the positively correlated genes in oral cancer. (b) Significantly enriched KEGG pathways of the negatively correlated genes in oral cancer. (c) Significantly enriched KEGG pathways of the negatively correlated genes in non-oral cancer. The left Y-axis shows the KEGG pathway. The X-axis shows the gene ratio.

Microbial differences between oral and non-oral head and neck squamous cell carcinomas (HNSCC)

Pathways correlated with enriched bacteria

Figure 4

Graphical summary of this study

Our study showed differences in the positive and negative KEGG pathways of the oral cancer-associated bacteria *Selenomonas*, *Fusobacterium*, and *Treponema* and the non-oral cancer-associated bacteria *Clostridium* and *Massilia*.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile.jpg](#)
- [Additionalfile.docx](#)